TY - JOUR
T1 - Current considerations for clinical management and care of non-alcoholic fatty liver disease
T2 - Insights from the 1st International Workshop of the Canadian NASH Network (CanNASH)
AU - Sebastiani, Giada
AU - Patel, Keyur
AU - Ratziu, Vlad
AU - Feld, Jordan J.
AU - Neuschwander-Tetri, Brent A.
AU - Pinzani, Massimo
AU - Petta, Salvatore
AU - Berzigotti, Annalisa
AU - Metrakos, Peter
AU - Shoukry, Naglaa
AU - Brunt, Elizabeth M.
AU - Tang, An
AU - Cobbold, Jeremy F.
AU - Ekoe, Jean Marie
AU - Seto, Karen
AU - Ghali, Peter
AU - Chevalier, Stéphanie
AU - Anstee, Quentin M.
AU - Watson, Heather
AU - Bajaj, Harpreet
AU - Stone, James
AU - Swain, Mark G.
AU - Ramji, Alnoor
N1 - Publisher Copyright:
© 2022, University of Toronto Press. All rights reserved.
PY - 2022
Y1 - 2022
N2 - Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, which can progress to liver cirrhosis and related end-stage complications. Type 2 diabetes and obesity represent the main risk factors for the disease. The Canadian NASH Network is a national collaborative organization of health care professionals and researchers with a primary interest in enhancing understanding, care, education, and research around NAFLD, with a vision of best practices for this disease state. At the 1st International Workshop of the CanNASH network in April 2021, a joint event with the single topic conference of the Canadian Association for the Study of the Liver (CASL), clinicians, epidemiologists, basic scientists, and community members came together to share their work under the theme of NASH. This symposium also marked the initiation of collaborations between Canadian and other key opinion leaders in the field representative of international liver associations. The main objective is to develop a policy framework that outlines specific targets, suggested activities, and evidence-based best practices to guide provincial, territorial, and federal organizations in developing multidisciplinary models of care and strategies to address this epidemic.
AB - Non-alcoholic fatty liver disease (NAFLD) affects approximately 8 million Canadians. NAFLD refers to a disease spectrum ranging from bland steatosis to non-alcoholic steatohepatitis (NASH). Nearly 25% of patients with NAFLD develop NASH, which can progress to liver cirrhosis and related end-stage complications. Type 2 diabetes and obesity represent the main risk factors for the disease. The Canadian NASH Network is a national collaborative organization of health care professionals and researchers with a primary interest in enhancing understanding, care, education, and research around NAFLD, with a vision of best practices for this disease state. At the 1st International Workshop of the CanNASH network in April 2021, a joint event with the single topic conference of the Canadian Association for the Study of the Liver (CASL), clinicians, epidemiologists, basic scientists, and community members came together to share their work under the theme of NASH. This symposium also marked the initiation of collaborations between Canadian and other key opinion leaders in the field representative of international liver associations. The main objective is to develop a policy framework that outlines specific targets, suggested activities, and evidence-based best practices to guide provincial, territorial, and federal organizations in developing multidisciplinary models of care and strategies to address this epidemic.
KW - Biomedical
KW - Canadian NASH Network
KW - Clinical
KW - Diabetes
KW - Epidemiological
KW - Non-alcoholic fatty liver disease
KW - Non-alcoholic steatohepatitis
KW - Public health
UR - http://www.scopus.com/inward/record.url?scp=85136772064&partnerID=8YFLogxK
U2 - 10.3138/canlivj-2021-0030
DO - 10.3138/canlivj-2021-0030
M3 - Article
C2 - 35990786
AN - SCOPUS:85136772064
SN - 2561-4444
VL - 5
SP - 61
EP - 90
JO - Canadian Liver Journal
JF - Canadian Liver Journal
IS - 1
ER -